Medication Summary

Pacemaker-mediated tachycardia (PMT) is treated by reprogramming the pacemaker. If this is not possible, in some instances, medication to block retrograde conduction may be needed. In rare circumstances, ablation of retrograde conduction pathway (AV node or accessory pathway) is necessary.

Monteil B, Ploux S, Eschalier R, et al. Pacemaker-mediated tachycardia: manufacturer specifics and spectrum of cases. Pacing Clin Electrophysiol. 2015 Dec. 38(12):1489-98. [QxMD MEDLINE Link].
Love CJ. Pacemaker troubleshooting and follow-up. In: Ellenbogen KA, Kay GN, Lau CP, Wilkoff BL, eds. Clinical Cardiac Pacing Defibrillation and Resynchronization Therapy. 3rd ed. Philadelphia, PA: Elsevier; 2007. 1005-62.
Sharma PS, Kaszala K, Tan AY, et al. Repetitive nonreentrant ventriculoatrial synchrony: an underrecognized cause of pacemaker-related arrhythmia. Heart Rhythm. 2016 Aug. 13(8):1739-47. [QxMD MEDLINE Link].
Gjermeni E, Doering M, Richter S, Hindricks G, Bode K. Novel pacemaker-mediated arrhythmia without ventriculoatrial conduction can induce atrial fibrillation. JACC Clin Electrophysiol. 2021 Jan. 7(1):1-5. [QxMD MEDLINE Link]. [Full Text].
Richter S, Muessigbrodt A, Salmas J, et al. Ventriculoatrial conduction and related pacemaker-mediated arrhythmias in patients implanted for atrioventricular block: an old problem revisited. Int J Cardiol. 2013 Oct 9. 168(4):3300-8. [QxMD MEDLINE Link].
Frumin H, Furman S. Endless loop tachycardia started by an atrial premature complex in a patient with a dual chamber pacemaker. J Am Coll Cardiol. 1985 Mar. 5(3):707-10. [QxMD MEDLINE Link].
Abu-haniyeh A, Hajouli S. Pacemaker mediated tachycardia. StatPearls [Internet]. 2022 Jan. [QxMD MEDLINE Link]. [Full Text].
Greenspon AJ, Greenberg RM, Frankl WS. Tracking of atrial flutter during DDD pacing: another form of pacemaker-mediated tachycardia. Pacing Clin Electrophysiol. 1984 Nov. 7(6 pt 1):955-60. [QxMD MEDLINE Link].
Rozanski JJ, Blankstein RL, Lister JW. Pacer arrhythmias: myopotential triggering of pacemaker mediated tachycardia. Pacing Clin Electrophysiol. 1983 Jul. 6(4):795-7. [QxMD MEDLINE Link].
Griffin J, Smithline H, Cook J. Runaway pacemaker: a case report and review. J Emerg Med. 2000 Aug. 19(2):177-81. [QxMD MEDLINE Link].
Klementowicz PT, Furman S. Selective atrial sensing in dual chamber pacemakers eliminates endless loop tachycardia. J Am Coll Cardiol. 1986 Mar. 7(3):590-4. [QxMD MEDLINE Link]. [Full Text].
Frohlig G, Schwerdt H, Schieffer H, Bette L. Atrial signal variations and pacemaker malsensing during exercise: a study in the time and frequency domain. J Am Coll Cardiol. 1988 Apr. 11(4):806-13. [QxMD MEDLINE Link]. [Full Text].
Horie K, Otomo K, Mori S, Kikuchi Y, Meguro T. Uncommon presentation of drug-refractory pacemaker-mediated common atrioventricular nodal reentrant tachycardia and a simple solution by reprogramming. Intern Med. 2015. 54(9):1063-6. [QxMD MEDLINE Link].
Ip JE, Lerman BB. Validation of device algorithm to differentiate pacemaker-mediated tachycardia from tachycardia due to atrial tracking. Heart Rhythm. 2016 Aug. 13(8):1612-7. [QxMD MEDLINE Link].
Strik M, Frontera A, Eschalier R, et al. Accuracy of the pacemaker-mediated tachycardia algorithm in Boston Scientific devices. J Electrocardiol. 2016 Jul-Aug. 49(4):522-9. [QxMD MEDLINE Link]. [Full Text].

Media Gallery

Pacemaker-Mediated Tachycardia. Telemetered ECG tracing with surface lead II (top) and intracardiac electrograms (atrial electrogram [center] and ventricular electrogram [lower]) and marker channel (bottom) showing pacemaker-mediated tachycardia (PMT). The intracardiac markers indicate that the retrograde P waves, labeled AS for atrial-sensed event, occur 280 milliseconds after the ventricular-paced beats, labeled VP.
Pacemaker-Mediated Tachycardia. Telemetered ECG tracing showing atrioventricular (AV)–paced rhythm at 60/min after termination of the pacemaker-mediated tachycardia (PMT). The tracing, from top to bottom, shows lead II, atrial electrogram, ventricular electrogram, and marker channels. The intracardiac markers indicate the rhythm is atrial paced (AP) and ventricular paced (VP). Note that the VP beats are ventricular pseudofusion beats.
Pacemaker-Mediated Tachycardia. This is a typical example of PMT with ventricular pacing at maximum tracking rate (VP-MT) and then termination of the tachycardia as the atrial sensing (AS) is in the postventricular atrial refractory period (PVARP). This is due to PVARP extension, which is a feature of this particular pacemaker. The solid line indicates where PMT is detected and this is the point at which PVARP extension occurs. As this electrogram was detected, but not sensed to be acted upon, the ventricular tracking stopped and the tachycardia terminated. In some cases, pacemakers have a program to lengthen the PVARP after PMT detection to potentially stop the tachycardia. Alternatively, prevention of one ventricular paced beat can also stop the tachycardia. Some pacemakers use this algorithm.

of 3

Author

Brian Olshansky, MD, FESC, FAHA, FACC, FHRS Professor Emeritus of Medicine, Department of Internal Medicine, University of Iowa College of Medicine

Brian Olshansky, MD, FESC, FAHA, FACC, FHRS is a member of the following medical societies: American College of Cardiology, American Heart Association, Cardiac Electrophysiology Society, European Society of Cardiology, Heart Rhythm Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Astra Zeneca, Artivion<br/>DSMB.

Coauthor(s)

Chirag M Sandesara, MD, FACC, FHRS Clinical Cardiac Electrophysiologist

Chirag M Sandesara, MD, FACC, FHRS is a member of the following medical societies: American College of Cardiology, Heart Rhythm Society

Disclosure: Nothing to disclose.

Noel G Boyle, MB, BCh, MD, PhD Professor of Medicine, UCLA Cardiac Arrhythmia Center, Ronald Reagan UCLA Medical Center

Noel G Boyle, MB, BCh, MD, PhD is a member of the following medical societies: American College of Cardiology, European Society of Cardiology, Heart Rhythm Society, American College of Physicians

Disclosure: Nothing to disclose.

Rakesh Gopinathannair, MD, MA Director of Cardiac Electrophysiology, University of Louisville; Assistant Professor of Medicine, Division of Cardiovascular Medicine, University of Louisville School of Medicine

Rakesh Gopinathannair, MD, MA is a member of the following medical societies: American College of Cardiology, Heart Rhythm Society

Disclosure: Received consulting fee from St. Jude Medical for consulting; Received honoraria from Boston Scientific for speaking and teaching.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Chief Editor

Jose M Dizon, MD Professor of Clinical Medicine, Clinical Electrophysiology Laboratory, Division of Cardiology, Columbia University College of Physicians and Surgeons; Attending Physician, Department of Medicine, New York-Presbyterian/Columbia University Medical Center

Jose M Dizon, MD is a member of the following medical societies: American College of Cardiology, Heart Rhythm Society

Disclosure: Nothing to disclose.

Additional Contributors

Justin D Pearlman, MD, ME, PhD, FACC, MA Chief, Division of Cardiology, Director of Cardiology Consultative Service, Director of Cardiology Clinic Service, Director of Cardiology Non-Invasive Laboratory, Chair of Institutional Review Board, University of California, Los Angeles, David Geffen School of Medicine

Justin D Pearlman, MD, ME, PhD, FACC, MA is a member of the following medical societies: American College of Cardiology, International Society for Magnetic Resonance in Medicine, American College of Physicians, American Federation for Medical Research, Radiological Society of North America

Disclosure: Nothing to disclose.

Pacemaker-Mediated Tachycardia Medication

Medication Summary

References

Tables

Contributor Information and Disclosures

What would you like to print?